Mr. Daniel P. O’Day serves as the Chairman and Chief Executive Officer of the company since 2019. Prior to this, he was the Chief Executive Officer of Roche Pharmaceuticals. Mr. O’Day held a number of executive positions in the company’s pharmaceutical and diagnostics divisions in North America, Europe and Asia.

Mr. Andrew D. Dickinson has been the Chief Financial Officer since 2016. Prior to this, he was the Head of the company’s Corporate Development and Strategy Group. Mr. Dickinson also served as the Co-Head of Healthcare Investment Banking at Lazard, General Counsel and Vice President of Corporate Development at Myogen, Inc.

Mr. Merdad V. Parsey has been the Chief Medical Officer of the company since 2019. Prior to this, he was the Senior Vice President of Early Clinical Development at Genentech. Mr. Parsey also served as the President and Chief Executive Officer of Sagimet BioSciences and held development roles at Sepracor, Regeneron and Merck, Assistant Professor of Medicine and Director of Critical Care Medicine at the New York University School of Medicine.

Ms. Johanna Mercier has been the Chief Commercial Officer since 2019. Prior to this, she held a number of executive leadership positions at Bristol-Myers Squibb. She currently serves on the Board of Directors of Neurocrine Biosciences Inc. and the University of Southern California's Leonard D. Schaeffer Center for Health Policy and Economics.